Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report)‘s stock had its “overweight” rating restated by equities research analysts at Cantor Fitzgerald in a research report issued on Friday, Benzinga reports. They presently have a $300.00 price objective on the biotechnology company’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 30.07% from the stock’s current price.
Several other research firms have also recently weighed in on ASND. UBS Group reiterated a “buy” rating and issued a $344.00 price objective on shares of Ascendis Pharma A/S in a report on Wednesday, September 16th. HC Wainwright set a $344.00 target price on shares of Ascendis Pharma A/S in a research note on Thursday, September 10th. Raymond James Financial cut shares of Ascendis Pharma A/S from a “strong-buy” rating to an “outperform” rating and set a $287.00 price target on the stock. in a research note on Tuesday, September 15th. Stifel Nicolaus decreased their target price on shares of Ascendis Pharma A/S from $328.00 to $326.00 and set a “buy” rating for the company in a report on Monday, August 31st. Finally, Wedbush reiterated an “outperform” rating and issued a $327.00 target price on shares of Ascendis Pharma A/S in a research note on Tuesday, September 1st. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $310.75.
Check Out Our Latest Stock Report on Ascendis Pharma A/S
Ascendis Pharma A/S Price Performance
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last released its earnings results on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing the consensus estimate of $1.71 by ($0.68). Ascendis Pharma A/S had a net margin of 70.99% and a return on equity of 32.54%. The business had revenue of $387.22 million for the quarter, compared to the consensus estimate of $376.75 million. On average, equities analysts predict that Ascendis Pharma A/S will post 3.69 EPS for the current fiscal year.
Insider Activity
In other news, Director Jean-Jacques Bienaimé acquired 2,000 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The shares were bought at an average price of $246.33 per share, with a total value of $492,660.00. Following the completion of the purchase, the director directly owned 2,900 shares in the company, valued at $714,357. This trade represents a 222.22% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Mads Bodenhoff sold 3,000 shares of Ascendis Pharma A/S stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total value of $810,570.00. Following the completion of the transaction, the senior vice president owned 3,000 shares in the company, valued at $810,570. This represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 40.00% of the company’s stock.
Institutional Investors Weigh In On Ascendis Pharma A/S
Several institutional investors and hedge funds have recently made changes to their positions in ASND. Perceptive Advisors LLC boosted its holdings in shares of Ascendis Pharma A/S by 41.6% in the 1st quarter. Perceptive Advisors LLC now owns 1,531,421 shares of the biotechnology company’s stock valued at $350,282,000 after acquiring an additional 450,000 shares during the last quarter. Fred Alger Management LLC raised its position in Ascendis Pharma A/S by 106.3% during the fourth quarter. Fred Alger Management LLC now owns 352,109 shares of the biotechnology company’s stock valued at $75,084,000 after acquiring an additional 181,408 shares in the last quarter. Sei Investments Co. raised its position in Ascendis Pharma A/S by 24.8% during the first quarter. Sei Investments Co. now owns 351,146 shares of the biotechnology company’s stock valued at $80,318,000 after acquiring an additional 69,673 shares in the last quarter. Pictet Asset Management Holding SA lifted its holdings in Ascendis Pharma A/S by 243.0% in the first quarter. Pictet Asset Management Holding SA now owns 251,833 shares of the biotechnology company’s stock valued at $56,907,000 after acquiring an additional 178,415 shares during the period. Finally, Candriam S.C.A. boosted its position in Ascendis Pharma A/S by 23.2% in the 1st quarter. Candriam S.C.A. now owns 230,278 shares of the biotechnology company’s stock worth $52,671,000 after purchasing an additional 43,338 shares in the last quarter.
About Ascendis Pharma A/S
Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company uses its proprietary TransCon technology platform to design long-acting medicines intended to improve the effectiveness, convenience, and tolerability of established treatments.
Ascendis’ marketed products include Skytrofa (lonapegsomatropin-tcgd), a long-acting growth hormone approved for the treatment of growth hormone deficiency in children, and Yorvipath (palopegteriparatide), a hormone replacement therapy for adults with hypoparathyroidism.
Read More
- Five stocks we like better than Ascendis Pharma A/S
- Stitch Fix Stock Plunges as Guidance Puts the Turnaround on Pause
- Harley-Davidson Insiders Are Buying: Is HOG Finally Turning Around?
- 2 China-Focused ETFs For After the Trump-Xi Summit
- 3 Dividend Stocks Investors May Be Missing in 2026
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
